{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T02:13:21Z","timestamp":1792548801565,"version":"4.5.0"},"reference-count":61,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T00:00:00Z","timestamp":1687305600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The objective of this study was to review the safety and efficacy of deucravacitinib, a tyrosine kinase 2 (TYK2) inhibitor for moderate to severe plaque psoriasis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Sources<\/jats:title>\n                    <jats:p>Literature was reviewed from MEDLINE and Clinicaltrials.gov up to December 2022 using the terms \u201cdeucravacitinib\u201d and \u201cBMS-986165.\u201d<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Selection<\/jats:title>\n                    <jats:p>Relevant articles in English relating to the pharmacodynamics, pharmacokinetics, efficacy, and safety of deucravacitinib were included. A total of 6 trial results were included.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Selection and Data Extraction<\/jats:title>\n                    <jats:p>Deucravacitinib showed clinical efficacy across all the phase II and III clinical trials. Excluding the long-term extension study, there were 2248 subjects across all studies, with 63.2% of patients receiving deucravacitinib 6 mg daily. Of these subjects, the average proportion achieving a PASI 75 (a reduction of greater than 75% in the Psoriasis Area and Severity Index) at week 16 was 65.1%. Patients receiving deucravacitinib 6 mg once daily had a higher rate of achieving both PASI 75 response and a Static Physician\u2019s Global Assessment (sPGA) score of 0 or 1, compared with oral apremilast 30 mg twice daily. The safety profile of deucravacitinib includes mild adverse events (AEs), most commonly nasopharyngitis, with serious AEs reported ranging from 1.35% to 9.5%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Relevance to Patient Care and Clinical Practice in Comparison With Existing Medications<\/jats:title>\n                    <jats:p>While many available therapies for moderate to severe plaque psoriasis rely on an injectable dosage form or extensive monitoring, deucravacitinib can potentially reduce patient medication-related burden. This review summarizes the efficacy and safety of oral deucravacitinib for the treatment of severe plaque psoriasis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Deucravacitinib shows a consistent efficacy and safety profile as the first oral TYK2 inhibitor approved for adult patients with moderate to severe plaque psoriasis who are eligible for systemic therapy or phototherapy treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10600280231153863","type":"journal-article","created":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T06:49:56Z","timestamp":1687330196000},"page":"416-427","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":46,"title":["Deucravacitinib: The First FDA-Approved Oral TYK2 Inhibitor for Moderate to Severe Plaque Psoriasis"],"prefix":"10.1177","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6282-801X","authenticated-orcid":false,"given":"Thu Minh","family":"Truong","sequence":"first","affiliation":[{"name":"Department of Dermatology, Rutgers Robert Wood Johnson Medical School, Somerset, NJ, USA"},{"name":"School of Medicine, Rutgers New Jersey Medical School, Newark, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaurav N.","family":"Pathak","sequence":"additional","affiliation":[{"name":"School of Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Singal","sequence":"additional","affiliation":[{"name":"School of Medicine, Rutgers New Jersey Medical School, Newark, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7223-1340","authenticated-orcid":false,"given":"Viktoriia","family":"Taranto","sequence":"additional","affiliation":[{"name":"NYIT College of Osteopathic Medicine, Glen Head, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Babar K.","family":"Rao","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Rutgers Robert Wood Johnson Medical School, Somerset, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2023,6,21]]},"reference":[{"key":"bibr1-10600280231153863","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.05.089"},{"key":"bibr2-10600280231153863","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.033217"},{"key":"bibr3-10600280231153863","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.02.039"},{"key":"bibr4-10600280231153863","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20061475"},{"key":"bibr5-10600280231153863","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21207488"},{"key":"bibr6-10600280231153863","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a015354"},{"key":"bibr7-10600280231153863","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20184347"},{"key":"bibr8-10600280231153863","doi-asserted-by":"publisher","DOI":"10.1111\/j.0022-202X.2004.23511.x"},{"key":"bibr9-10600280231153863","doi-asserted-by":"publisher","DOI":"10.12788\/j.sder.2018.011"},{"key":"bibr10-10600280231153863","doi-asserted-by":"publisher","DOI":"10.1016\/s0190-9622(99)70112-x"},{"key":"bibr11-10600280231153863","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14204"},{"key":"bibr12-10600280231153863","doi-asserted-by":"publisher","DOI":"10.1159\/000500116"},{"key":"bibr13-10600280231153863","doi-asserted-by":"publisher","DOI":"10.7573\/dic.2021-9-3"},{"key":"bibr14-10600280231153863","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.743180"},{"key":"bibr15-10600280231153863","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-214065"},{"key":"bibr16-10600280231153863","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-028116"},{"key":"bibr17-10600280231153863","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2021.2007"},{"key":"bibr18-10600280231153863","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.108326"},{"key":"bibr19-10600280231153863","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.143.12.1493"},{"key":"bibr20-10600280231153863","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2008.08779.x"},{"key":"bibr21-10600280231153863","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.150638"},{"key":"bibr22-10600280231153863","first-page":"1706","volume":"2009","author":"Naldi L","year":"2009","journal-title":"BMJ Clin Evid"},{"key":"bibr23-10600280231153863","unstructured":"Sotyktu (deucravacitinib) [package insert]. Bristol-Myers Squibb Company; 2022. Accessed January 9, 2023. https:\/\/packageinserts.bms.com\/pi\/pi_sotyktu.pdf"},{"key":"bibr24-10600280231153863","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221664"},{"key":"bibr25-10600280231153863","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2010.04.026"},{"key":"bibr26-10600280231153863","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01862"},{"key":"bibr27-10600280231153863","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0701-9"},{"key":"bibr28-10600280231153863","doi-asserted-by":"publisher","DOI":"10.4331\/wjbc.v13.i1.1"},{"key":"bibr29-10600280231153863","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2021.11.001"},{"key":"bibr30-10600280231153863","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-021-00596-8"},{"key":"bibr31-10600280231153863","volume-title":"Oral presentation at the European Academy of Dermatology and Venereology 31st Congress","author":"Imafuku S"},{"key":"bibr32-10600280231153863","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1806382"},{"key":"bibr33-10600280231153863","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.08.061"},{"key":"bibr34-10600280231153863","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.07.002"},{"key":"bibr35-10600280231153863","volume-title":"Oral presentation at the European Academy of Dermatology and Venereology (EADV) 31st Congress","author":"Zhang JZ"},{"key":"bibr36-10600280231153863","unstructured":"Warren RB, Armstrong AW, Imafuku S, et al. Deucravacitinib, an oral, selective tyrosine kinase 2 (TYK2) inhibitor, versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy analysis by prior treatment in the phase 3 POETYK PSO-1 and PSO-2 trials. Oral presentation at the European Academy of Dermatology and Venereology 30th Congress (Virtual); September-October 2021. https:\/\/www.eadvcongress2021.org\/index.php\/home\/the-congress\/"},{"key":"bibr37-10600280231153863","volume-title":"Oral presentation at the European Academy of Dermatology and Venereology 31st Congress","author":"Lebwohl M"},{"key":"bibr38-10600280231153863","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.1056"},{"issue":"2","key":"bibr39-10600280231153863","first-page":"318","volume":"34","author":"Hodge J","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"bibr40-10600280231153863","unstructured":"Xeljanz (tofacitinib) [package insert]. Pfizer, Inc.; 2018. Accessed January 9, 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/203214s018lbl.pdf"},{"key":"bibr41-10600280231153863","unstructured":"Olumiant (baricitinib) [package insert]. Lilly USA, LLC; 2022. Accessed January 9, 2023. https:\/\/uspl.lilly.com\/olumiant\/olumiant.html#pi"},{"key":"bibr42-10600280231153863","unstructured":"Rinvoq (upadacitinib) [package insert]. AbbVie Inc; 2022. Accessed January 9, 2023. https:\/\/www.rxabbvie.com\/pdf\/rinvoq_pi.pdf"},{"key":"bibr43-10600280231153863","unstructured":"Cibinqo (abrocitinib) [package insert]. Pfizer Inc; 2022. Accessed January 9, 2023. https:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=16652"},{"key":"bibr44-10600280231153863","doi-asserted-by":"publisher","DOI":"10.1002\/art.40841"},{"key":"bibr45-10600280231153863","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-021-00618-3"},{"key":"bibr46-10600280231153863","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2022.0029"},{"key":"bibr47-10600280231153863","volume":"23","author":"Wu JJ.","year":"2017","journal-title":"Am J Manag Care"},{"key":"bibr48-10600280231153863","doi-asserted-by":"publisher","DOI":"10.1159\/000455042"},{"key":"bibr49-10600280231153863","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-015-0151-4"},{"key":"bibr50-10600280231153863","doi-asserted-by":"publisher","DOI":"10.1111\/jan.13818"},{"key":"bibr51-10600280231153863","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-021-00649-y"},{"key":"bibr52-10600280231153863","doi-asserted-by":"publisher","DOI":"10.2147\/BTT.S188286"},{"key":"bibr53-10600280231153863","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2016.04.082"},{"key":"bibr54-10600280231153863","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60725-4"},{"key":"bibr55-10600280231153863","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.12668"},{"key":"bibr56-10600280231153863","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1512711"},{"key":"bibr57-10600280231153863","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2012.04644.x"},{"key":"bibr58-10600280231153863","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2011.03992.x"},{"key":"bibr59-10600280231153863","doi-asserted-by":"publisher","DOI":"10.1016\/j.annder.2018.11.011"},{"key":"bibr60-10600280231153863","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2015.296"},{"issue":"1","key":"bibr61-10600280231153863","first-page":"18","volume":"10","author":"Hyde K","year":"2018","journal-title":"Am J Pharm Benefits"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280231153863","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10600280231153863","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280231153863","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:13:03Z","timestamp":1777374783000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10600280231153863"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,21]]},"references-count":61,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["10.1177\/10600280231153863"],"URL":"https:\/\/doi.org\/10.1177\/10600280231153863","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,21]]}}}